Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 187, Issue 5, 2003, Pages 758-768

  Subramaniam, Krishanthi S ^a   Segal, Robert ^a   Lyles, Robert H ^b   Rodriguez Barradas, Maria C ^c   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; ZIDOVUDINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS LOAD;

ADULT; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENES, IMMUNOGLOBULIN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN VARIABLE REGION; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0037333265     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368331     Document Type: Article

References (52)

1. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1):S5-14.
2. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050-6.
3. Valdez H, Purvis S, Asaad R, et al. Levels of proinflammatory cytokines in plasma after pneumococcal immunization in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1999; 6:427-8.
4. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314-24.
5. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800.
6. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160:2633-8.
7. French N, Nakinyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
8. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857-62.
9. Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol 2001; 22:255-61.
10. Begemann M, Policar M. Pneumococcal vaccine failure in an HIV-infected patient with fatal pneumococcal sepsis and HCV-related cirrhosis. Mt Sinai J Med 2001; 68:396-9.
11. Lane CH, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B cell activation and immunoregulation in patients with AIDS. N Engl J Med 1983; 309:453-8.
12. Chang Q, Abadi J, Alpert P, Pirofski LA. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. J Infect Dis 2000; 181:1313-21.
13. Shaw DR, Kirkham P, Schroeder HW Jr, Roben P, Silverman GJ. Structure-function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Ann NY Acad Sci 1995; 764:370-3.
14. Russell N, Corvalan JR, Gallo ML, Davis CG, Pirofski LA. Production of protective human anti-pneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect Immun 2000; 68:1820-6.
15. Zhong Z, Burns T, Chang Q, Carroll M, Pirofski LA. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect Immun 1999; 67:4119-27.
16. H3 gene segment usage. J Infect Dis 1998; 178:707-16.
17. Lucas AH, Granoff DM, Mandrell RE, Connolly CC, Shah AS, Powers DC. Oligoclonality of serum immunoglobulin G antibody responses to Streptococcus pneumoniae capsular polysaccharide serotypes 6B, 14, and 23F. Infect Immun 1997; 65:5103-9.
18. Chang Q, Zhong Z, Lees A, Pekna M, Pirofski LA. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect Immun 2002; 70:4977-86.
19. Scamurra RW, Miller DJ, Abrahamsen M, et al. Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J Immunol 2000; 164:5482-91.
20. H3 (D12 idiotope) B cells in vivo. J Acquir Immune Defic Syndr 1994; 7:641-5.
21. H3 gene family expression in plasma cells of HIV-infected patients. Int Immunol 1996; 8:1329-33.
22. H1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection. Eur J Immunol 1995; 25:1524-8.
23. H3 gene products: natural ligands for HIV gp120. Science 1993; 261:1588-91.
24. Fleuridor R, Lyles RH, Pirofski LA. Quantitative and qualitative differences in the serum antibody profiles of HIV-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis 1999; 180:1526-36.
25. Potter KN, Li Y, Mageed RA, Jefferis R, Capra JD. Anti-ldiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FW1, CDR2 and FW3. Mol Immunol 1998; 35:1179-87.
26. Lucas AH, Moulton KD, Tang VR, Reason DC. Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23E. Infect Immun 2001; 69:853-64.
27. Sun Y, Park MK, Kim J, Nahm MH, Solomon A. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect Immun 1999; 67:1172-9.
28. H family in HIV-infected patients: modulation by triple combination therapy. AIDS Res Hum Retroviruses 1999; 15:315-6.
29. Silverman GJ, Pires R, Bouvet JP. An endogenous sialoprotein and a bacterial B cell superantigen compete in their VH family-specific binding interactions with human Igs. J Immunol 1996; 157:4496-502.
30. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4.
31. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
32. Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretrovirat therapy. AIDS 1998; 12:F217-23.
33. Pirofski LA, Casadevatl A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998; 11:1-26.
34. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunot 1995; 13:655-92.
35. Kroon FP, van Dissel IT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcat polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999; 18:524-30.
36. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal potysaccharide vaccine after prior immunization with conjugate pneumococcat vaccine in HiV-infected adults. Vaccine 2000; 19:886-94.
37. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173:83-90.
38. Weiss PJ, Wallace MR, Oldfield EC3, O'Brien J, Janoff EN. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995; 171:1217-22.
39. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165:553-6.
40. Mascart-Lemone F, Libin GM, Crusiaux A, et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine J infect Dis 1995; 172:1253-60.
41. - lymphocytes. AIDS 1994; 8:469-76.
42. Vandenbruaene M, Colebunders R, Mascart-Lemone F, et al. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease. J Infect Dis 1995; 172:551-3.
43. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-sterm immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-69.
44. Hartigan PM, Hamilton JD, Simberkoff MS. Early zidovudine and survival in HIV infection Veterans Affairs AIDS Cooperative Studies Group. N Engl J Med 1992; 327:814-5.
45. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991; 164:761-4.
46. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53.
47. Elkins KL, Stashak PW, Baker PJ. Mechanisms of specific immunological unresponsiveness to bacterial lipopolysaccharides. Infect Immun 1987; 55:3093-102.
48. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients inletted with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-21.
49. Chong Y, Ikematsu H, Ariyama I, et al. Evidence of B cell clonal expansion in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2001; 17:1507-15.
50. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood 1998; 92:1317-23.
51. Nagase H, Agematsu K, Kitano K, et al. Mechanism of hypergamma-gtobulinemia by HIV infection: circulating memory B-celt reduction with plasmacytosis. Clin Immunol 2001; 100:250-9.
52. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001; 98:10362-7.